THNR vs. CANC ETF Comparison

Comparison of Amplify Weight Loss Drug & Treatment ETF (THNR) to Tema Oncology ETF (CANC)
THNR

Amplify Weight Loss Drug & Treatment ETF

THNR Description

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

Grade (RS Rating)

Last Trade

$26.31

Average Daily Volume

10,215

Number of Holdings *

7

* may have additional holdings in another (foreign) market
CANC

Tema Oncology ETF

CANC Description Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Grade (RS Rating)

Last Trade

$27.48

Average Daily Volume

19,625

Number of Holdings *

8

* may have additional holdings in another (foreign) market
Performance
Period THNR CANC
30 Days 3.88% 1.52%
60 Days 5.94%
90 Days -1.47%
12 Months
2 Overlapping Holdings
Symbol Grade Weight in THNR Weight in CANC Overlap
AMGN B 5.57% 3.37% 3.37%
MRK A 5.02% 5.26% 5.02%
Compare ETFs